|Bid||89.30 x N/A|
|Ask||89.31 x N/A|
|Day's Range||87.99 - 90.10|
|52 Week Range||77.18 - 105.00|
|Beta (5Y Monthly)||0.42|
|PE Ratio (TTM)||85.05|
|Earnings Date||Oct 23, 2020 - Oct 27, 2020|
|Forward Dividend & Yield||0.19 (0.22%)|
|Ex-Dividend Date||May 25, 2020|
|1y Target Est||73.49|
South Korean retail investors are stampeding into Chinese stocks in record numbers, ploughing hundreds of millions of dollars into a tech sector rush far removed from punishing taxes and regulations on investment at home. In July alone, South Korean investors spent $240 million buying shares in mainland China, data from the Korea Securities Depository (KSD) showed - their largest investment in mainland markets on record.
The fund’s top new picks have high financial strength Continue reading...
Heidelberg, Germany--(Newsfile Corp. - November 8, 2019) - Novaliq GmbH, a pharmaceutical company focusing on first- and best-in-class ocular therapeutics, and Jiangsu Hengrui Medicine Co., Ltd. (SSE: 600276), a fully integrated biopharmaceutical company based in China, announce today the closing of an exclusive license agreement to develop, manufacture and commercialize the innovative, water-free drugs NOV03 and CyclASol® for the treatment of dry eye disease in the People's Republic of China (including mainland China, Hong ...